Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/β-catenin signaling pathway by unknown
Liu et al. Journal of Ovarian Research 2014, 7:87
http://www.ovarianresearch.com/content/7/1/87RESEARCH Open AccessReduced expression of SOX7 in ovarian
cancer: a novel tumor suppressor through the
Wnt/β-catenin signaling pathway
Huidi Liu1,2,4, Zi-Qiao Yan1, Bailiang Li1, Si-Yuan Yin1, Qiang Sun1, Jun-Jie Kou1, Dan Ye1, Kelsey Ferns1,5,
Hong-Yu Liu3 and Shu-Lin Liu1,2,4*Abstract
Background: Products of the SOX gene family play important roles in the life process. One of the members,
SOX7, is associated with the development of a variety of cancers as a tumor suppression factor, but its relevance
with ovarian cancer was unclear. In this study, we investigated the involvement of SOX7 in the progression and
prognosis of epithelial ovarian cancer (EOC) and the involved mechanisms.
Methods: Expression profiles in two independent microarray data sets were analyzed for SOX7 between malignant
and normal tissues. The expression levels of SOX7 in EOC, borderline ovarian tumors and normal ovarian tissues
were measured by immunohistochemistry. We also measured levels of COX2 and cyclin-D1 to examine their
possible involvement in the same signal transduction pathway as SOX7.
Results: The expression of SOX7 was significantly reduced in ovarian cancer tissues compared with normal controls,
strongly indicating that SOX7 might be a negative regulator in the Wnt/β-catenin pathway in ovarian cancer. By
immunohistochemistry staining, the protein expression of SOX7 showed a consistent trend with that of the gene
expression microarray analysis. By contrast, the protein expression level of COX2 and cyclin-D1 increased as the
tumor malignancy progressed, suggesting that SOX7 may function through the Wnt/β-catenin signaling pathway
as a tumor suppressor. In comparison between the protein expression levels of SOX7 with pathological features of
the cancer, we found that SOX7 was down-regulated mainly in serous cystadenocarcinoma and advanced stages
of the cancers.
Conclusions: The expression of SOX7 correlates with tumor progression as a tumor suppressor, possibly through
the Wnt/β-catenin signaling pathway in ovarian cancers, suggesting that SOX7 may be a promising prognostic
marker.
Keywords: SOX7, Tumor suppressor, Ovarian cancer, Wnt/β-catenin signaling pathwayBackground
Ovarian cancer is one of the three most common can-
cers in female with high morbidity and mortality rates
[1]. The disease is also among the most lethal cancers in
females, primarily because of its aggressive metastasis
within the peritoneal cavity. It is hardly detectable at the
early stage, largely due to the lack of specific symptoms
and reliable screening [2,3]. Among all types, epithelial* Correspondence: slliu@ucalgary.ca
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unless otherwise stated.ovarian cancer (EOC) is the most common, accounting
for 85% to 90% of ovarian cancers [4], and this type is
highly lethal. This situation calls for the investigation of
pathogenesis of EOC and the identification of molecular
markers for early diagnosis or for use as targets in
treatment.
SOX7, a member of subfamily SOXF along with SOX17
and SOX18, has been identified as a developmental regu-
lator in hematopoiesis and cardiogenesis [5-9]. The hu-
man SOX7 gene is located at the chromosomal region of
8p23.1 and is approximately 7.7 kbps in length [10]; a fre-
quently methylated CpG island on the promoter region ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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expression. SOX7 is frequently down-regulated in many
human cancers, such as prostate, colon, lung, and breast
cancers, and its reduced expression often correlates with
poor prognoses [11-13]. It is reported that SOX7 can
directly bind β-catenin and negatively regulate its ac-
tivity [14,15].
The Wnt/β-catenin signal transduction pathway is
widely acknowledged as playing a dominating role in
human diseases, especially in the occurrence and devel-
opment of cancer [16]. Although the molecular mechan-
ism by which SOX7 produces its tumor suppressive
effects has yet to be fully determined, SOX7 has been
shown to interact with β-catenin and inhibit cell pro-
liferation mediated by the Wnt signaling pathways.
Evidence is accumulating to show that SOX7 may dis-
rupt the transcriptional function of the β-catenin-TCF/
LEF complex and inhibit the activity of Wnt target genes
including cyclin D1, c-Myc and COX-2 [15,17]. Add-
itionally, recent studies indicate that SOX7 may act as a
tumor suppressor [11,13,14]. Ectopic SOX7 expression is
reported to have a regulating function against cell growth
and promote apoptosis; meanwhile, SOX7 gene knock-
down may lead to neoplastic transformation [14,18]. As
SOX7 negatively regulates the Wnt/β-catenin signaling
pathway by impeding the transcriptional machinery of
β-catenin/TCF/LEF-1, inactivation of SOX7 may be
associated with the pathogenesis of cancers, e.g., endo-
metrial cancer and prostate cancer [14,15]. Additionally,
SOX7 may be involved in aspirin-mediated growth in-
hibition of COX2 colorectal cancer cells, in which as-
pirin may up-regulate the expression of SOX7 by
activating the MAPK [17]. There are also reports indi-
cating that the decreased expression of SOX7 is an im-
portant feature of lung adenocarcinoma [12]. Based on
whole genome analysis to measure the expression of
SOX7 on a series of non-small cell lung cancers
(NSCLC), investigators have shown that SOX7 is a
novel tumor suppressor gene silenced in the majority
of NSCLC [19]. Numerous studies also suggest that
promoter methylation might be an important mech-
anism of SOX7 down-regulation in breast cancer and
MDS [11,13]. On the other hand, reports are also
available to show that SOX7 mRNA is significantly
up-regulated in cancer, such as in pancreatic, gastric,
and esophageal cancer cell lines, as well as in primary
gastric cancer [20]. To date, nevertheless, the contri-
butions and molecular mechanisms of SOX7 in ovarian
cancer are largely unknown.
In this study, we investigated the changes and possible
roles of SOX7 in ovarian cancer using the microarray
gene expression techniques and validated the results
with clinical tissues. Both kinds of data showed that the
expression of SOX7 was significantly reduced in ovariancancer and the levels of expression were correlated with
tumour progression. This effect might be mediated by




Peroxidase-labeled rabbit-anti human IgG SOX7 (sc-
20093) was purchased from Santa cruz biotechnology.
Peroxidase-labeled rabbit-anti human IgG COX2 (BA3708)
and rabbit-anti human IgG cyclinD1 (BA0770) used in
immunohistochemistry were purchased from BOSTER Bio,
Wuhan, China. Histostain-Plus Kit (SP-9001) and 3, 3′-di-
aminobenzidine tetrahydrochoride Substrate Kit (ZLI-9032)
used in immunohistochemistry were purchased from ZSGB
Bio, Beijing, China.
Datasets and preprocessing
Two sets of normalized microarray gene expression data
with accession numbers GSE12470 and GSE27651 were
downloaded from the Gene Expression Omnibus data re-
pository (GEO, http://www.ncbi.nlm.nih.gov/geo/). Probe
sets that did not match any known Gene ID or that
matched multiple Gene IDs were abandoned. For each of
the samples, the expression values of the probe sets
matched to the same Entrez Gene ID were averaged as
the expression value of that Entrez Gene ID. Genes in
GSE27651, the expression of which significantly correlated
(Pearson correlation) with that of SOX7, were defined as
coexpression genes with SOX7. The pathway information
of Wnt/β-catenin was documented in Kyoto Encyclopedia
of Genes and Genomes (KEGG) website.
Functional enrichment analysis
The functional enrichment analysis was performed using
the Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 [21,22] and the biological pro-
cesses (BPs) within Gene Ontology (GO) were checked
for overrepresented function entities.
Clinical specimens
Clinical specimens were collected from the Department
of Pathology of the Third Affiliated Hospital of Harbin
Medical University from January to June 2008. All
patients were informed of the purpose of the study and
gave written informed consents. This work was reviewed
by the Harbin Medical University Ethics Committee and
was approved, consistent with the 1975 Declaration of
Helsinki. The stage and histological grades of all the
cases were determined according to the criteria of
FIGO. None of the patients received any chemotherapy
or radiotherapy before operation. Clinical information of
patients was obtained from medical records and pathology
reports.
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The samples were fixed in 10% neutral buffered formalin
and subsequently embedded in paraffin. The paraffin-
embedded tissues were cut at 3 μm, deparaffinized with
xylene and rehydrated for further peroxidase (DAB)
immunohistochemistry staining. After trypsinization, the
tissue slides were blocked with peroxidase and then were
incubated overnight with the primary antibodies against
respective target proteins (SOX7 Ab., Santa Cruz #sc-
20093; Rabbit Anti-COX2, ZSGB-BIO, Rabbit Anti-
CyclinD1, ZSGB-BIO) at a dilution of 1:100 at 4°C. After
washing, peroxidase labeled polymer and substrate-
chromogen were applied to visualize the staining of the
target proteins. Finally, the slides were counterstained
with hematoxylin.
Standard for evaluation
Immunostaining was scored by two independent experi-
enced pathologists, who were blinded to the clinicopa-
thological data and clinical outcomes of the patients. The
scores of the two pathologists were compared and any
discrepant scores were trained through re-examining the
staining by both pathologists to achieve a consensus score.
Tumor specimens were scored in a semi-quantitative
















Gene expression level of Sox
Figure 1 Down-regulated SOX7 in ovarian cancer. Box plot analysis of
normal peritoneum samples. A significant correlation was found between o
control. (Normal peritoneum mean: 53.96 vs. ovarian cancer mean: 3.50 FDstaining of the target proteins. The percentage scoring
of immunoreactive tumor cells was as follows: 0 (0%), 1
(1-10%), 2 (11-50%) and 3 (>50%). The staining intensity
was externally scored and stratified as follows: 0 (nega-
tive), 1 (weak), 2 (moderate) and 3 (strong). A final immu-
noreactivity score (IRS) was obtained for each of the cases
by multiplying the percentage and the intensity score. Pro-
tein expression levels were further analyzed by classifying
IRS values as low (based on an IRS value less than 4) or
high (based on an IRS value greater than 4).
Statistical analysis
The differentially expressed genes of ovarian cancers vs.
normal controls in GSE12470 were calculated by student-t
test and the false discovery rate was controlled using the
Benjamini–Hochberg procedure [23]. The gene expression
level of SOX7 was compared in groups of different malig-
nant states in GSE27651 using one-way analysis of vari-
ance (one-way ANOVA). The difference between each
pair of the groups was tested by multiple comparison tests
and the statistical significance level was given by a
student-t test.
For the immunohistochemistry experiment, SPSS ver-
sion 17.0 was used. Statistical analysis was performed
with Fisher’s exact test, chi square test and Spearman’sOvarian cancer
7 in normal vs. ovarian cancer tissues
SOX7 mRNA expression levels among ovarian cancer samples and
varian cancer and reduced SOX7 mRNA levels compared with normal
R =7.4e-07).


















Gene expression level of Sox7 in tissues of different malignant state
Figure 2 One-way ANOVA analysis of SOX7 mRNA expression levels among HOSE, SBOT, LG and HG. A significant correlation was found
in HOSE relative to SBOT (p = 0.033) and HOSE compared with LG (p = 0.007).
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considered statistically significant.
Results
Expression levels of SOX7 in ovarian cancer and normal
tissues
To investigate the correlation between SOX7 and the
state of ovarian cancer, we compared the SOX7 gene
expression profiles of forty-three serous ovarian cancers
and ten peritoneum controls in GSE12470, with the false





GO:0022613 ribonucleoprotein complex biogenesis
GO:0016071 mRNA metabolic process
GO:0006397 mRNA processing
GO:0000375 RNA splicing, via transesterification reactions
GO:0000377 RNA splicing, via transesterification reactions with bulged aden
GO:0000398 nuclear mRNA splicing, via spliceosome
GO:0042254 ribosome biogenesis
GO:0008380 RNA splicingthe expression of SOX7 was reduced significantly in
ovarian cancer tissues compared with normal controls
(ovarian cancer mean: 3.50 vs. normal peritoneum mean:
53.96, FDR =7.4e-07; Figure 1).
Correlation of reduced SOX7 expression with tumor
progression
We assessed the expression of SOX7 in ovarian tissues
of different tumor progression states. We used the gene
expression data set GSE27651, which profiled six human













Figure 3 Downstream genes chosen from KEGG annotated in Wnt/β-catenin pathway. Downstream genes in the Wnt/β-catenin pathway
are denoted in red. The figure is created based on KEGG pathway. Only a part of the pathway is shown for clarity.
Table 2 The Pearson correlation coefficients between the
expression levels of 13 genes and SOX7














Bold front denotes downstream genes in wnt signal pathway list in KEGG.
*Presents significant correlation.
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ian carcinomas (LG), and twenty-two high-grade serous
ovarian carcinomas (HG). As highly malignant cells are
believed to arise from ovarian carcinoma of low malig-
nancy, the expression value of SOX7 should be different
among tissues of different malignancy. Differences of
SOX7 gene expression were observed among the four
groups (p =0. 012) by one-way analysis of variance (one-
way ANOVA). Multiple comparisons showed significant
down-regulation of SOX7 mRNA expression compared
to HOSE in both SBOT (SBOT mean: 42.07 vs. HOSE
mean: 81.98, student-t p = 0.033) and LG (LG mean:
40.85 vs. HOSE mean: 81.98, student-t p = 0.007). The
amount of SOX7 expression in HG in comparison with
HOSE was similar, although the difference was not statis-
tically significant (Figure 2).
SOX7 as a negative regulator in Wnt/β-catenin pathway
in ovarian cancer
It has been reported that SOX7, a member of the SOX
family, functions as a transcriptional factor. To investigate
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genesis and progression of ovarian cancers, we analyzed
genes that were co-expressed with SOX7 and short-
listed 7933 genes by Pearson correlation (FDR < 0.01)
in GSE27651 (see Additional file 1: Table S1). Using
DAVID with a 5% FDR control, we found that the 7933
genes were significantly overrepresented in eleven GO-
biological processes involved mainly in transcription activ-
ities (Table 1). As SOX7 has been reported to block the
transcription of Wnt/β-catenin signaling pathway in various
cancers, we postulated that it might have the same function
in ovarian cancer. We chose thirteen genes from KEGG that
were annotated in the Wnt/β-catenin pathway as down-
stream or pivotal hub genes (Figure 3) and calculated the
Pearson correlation coefficients of expression levels betweenFigure 4 Immunohistochemical staining for SOX7, cyclinD1 and COX2
ovarian cancer. A. SOX7 strong positive staining in normal ovarian tissues
cancer. CyclinD1 weak positive staining in normal ovarian tissues and bord
weak positive staining in normal ovarian tissues, strong positive staining in
nucleus in in every SOX7-positive ovarian tissue section. Representative of
ovarian tissues, borderline ovarian tumors and ovarian cancer with anti-SOX
(c) and strong stain (d).the 13 genes and SOX7 (Table 2). We found that the expres-
sion of six of the 13 selected genes was significantly corre-
lated with that of SOX7, all negatively (binomial distribution
p = 0.0156). Additionally, a marginal correlation of cyclinD1
with SOX7 was observed (p = 0.0555). Interestingly, as
many as eleven of the 13 selected genes (except PPARD
and TCF7L1) were negatively correlated with SOX7 (bino-
mial distribution, p = 0.0112), suggesting that SOX7 could
be a negative regulator of the Wnt/β-catenin pathway.
Expression of SOX7, cyclin-D1 and COX2 proteins in normal
ovarian tissues, borderline ovarian tumors and ovarian
cancer
Eight of the ten analyzed normal ovarian tissue sections
were positive for SOX7 immunoreactivity, with moderatein normal ovarian tissues, borderline ovarian tumors and
and weak positive staining in borderline ovarian tumor and ovarian
erline ovarian tumor, strong positive staining in ovarian cancer. COX2
borderline ovarian tumor and ovarian cancer. B. SOX7 localizes to the
section (20 ×magnification) immunohistochemical stains of normal
7 antibody shown, from left to right, negative (a), weak (b), moderate
Table 3 Correlations of the SOX7 protein expression with










Serous 26 7 19
Mucinous 2 0 2
Endometrioid 3 1 2
FIGO stage 0.037
Early (I-II) 16 7 9
Advance (III-IV) 15 1 14
Pathology grade NS
Low (1) 4 1 3
High (2 + 3) 27 7 20
Age (years) NS
<40 0 0 0
40-60 21 5 16
> 60 10 3 7
Cyclin D1 rs = −0.583,
p < 0.001
Over-expression 26 8 18
Low-expression 5 0 5
COX2 rs = −0.618,
p < 0.001
Over-expression 27 5 22
Low-expression 4 3 1
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among the levels of staining intensity were not statistically
significant. A minority of the ovarian cancer tissue sec-
tions had positive SOX7 staining intensity, but negative or
weak SOX7 staining intensity was seen in most of the
malignant ovarian tissues (23/31; Figure 4B). SOX7 immu-
noreactivity was nucleonic in every SOX7-positive ovarian
tissue section. COX2 and cyclin-D1 are the target
genes in the β-catenin signal pathway. The immuno-
reactivity in COX2 and cyclin-D1 was crosscurrent
compared to SOX7 in our research, which is consistent
with the previous reports in other tissues (Figure 4A). For
simultaneous comparison, each type of ovarian tissues
used for photographing was from the same patient.
Relations between SOX7 and clinical or pathological
characteristics in patients with epithelial ovarian
carcinoma
We analyzed the correlation between SOX7 expression
and clinical or pathological characteristics of the tissues.
We observed that SOX7 was down-regulated mainly
in serous cystadenocarcinoma (19/31) but did not find
significant differences among the pathological types (i.e.,
serous cystadenocarcinoma, mucinous cystadenocarci-
noma, and endometrioid carcinoma). On the other hand,
we found that the down-regulation of SOX7 was signifi-
cantly associated with the advanced stages (III-IV; 14/31,
p = 0.037), although no relationship was observed between
SOX7 expression and other clinical features, such as path-
ology grade or age (Table 3). Correlation analysis showed
that SOX7 expression was negatively correlated with
COX2 (rs = −0.618, p < 0.001) and cyclinD1 (rs = −0.583,
p < 0.001), two specific downstream targets in the Wnt-
β-catenin pathway. The negative correlation of SOX7
with COX2 and cyclinD1 indicates a trend of inverse ex-
pression pattern of SOX7 to COX2 and cyclin D1.
Discussion
Ovarian cancer remains to be a leading cause of death
from gynecological malignancies. It is a huge challenge
of current basic and clinical research to seek novel
molecular markers for more accurate and efficient use in
early diagnosis, treatment or prognosis of ovarian can-
cer. In this study, we chose ovarian cancer to work on
primarily due to the fact that this disease is so devastat-
ing in females and that to date relatively little has been
done on SOX7 in ovarian cancer. Our results obtained
from different platforms indicate that the expression
levels of SOX7 were significantly reduced in all types of
ovarian cancers studied here, though at different extents.
LG is the most malignant among ovarian cancer and may
progress from SBOT, while HG, much less malignant than
LG, likely develops from other kinds of precursors, such
as normal epithelium of ovary or distal fallopian tube [24].HG is a well-differentiated neoplasm and closely re-
sembles normal tissues in many ways, so its prognosis is
generally much better than LG [25]. As a result, the gene
expression levels of SOX7 showed opposite tendencies to
malignancy degrees. Based on the findings in this study,
we propose that SOX7 is a key factor during ovarian
cancer progression and is a useful prognostic marker.
Of great significance, we found that SOX7 was nega-
tively correlated with Cyclin D1 and could be a negative
regulator of the Wnt/β-catenin pathway. Cyclin D1, which
controls the cell cycle, is the target gene of β-catenin and
plays an important role in ovarian cancer. It is known that
the Wnt/β-catenin signaling pathway is activated in epi-
thelial ovarian cancer [26] and strongly involved in ovarian
cancer development [27]. As SOX7 has been reported to
block the transcriptional function of the Wnt/β-catenin
signaling pathway and inhibit the activity of Wnt target
genes including cyclin D1, c-Myc and COX-2 [15,17], we
wondered whether there might be a correlation between
SOX7 and these supposed target genes. Our results dem-
onstrated that the expression levels of SOX7 and its
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ship, further supporting our hypothesis that SOX7 is a
negative regulator in the Wnt/β-catenin signaling pathway
in ovarian cancer. Although our data showed a marginal
correlation of cyclin D1 with SOX7 (p = 0.0555) at the
mRNA level, the correlation at the protein level was
strong, so both had similar trends.
SOX7, a member of the SOX-F subfamily encoding
transcription factors that have a pivotal role in cardio-
vascular development [8],has been implicated as a tumor
suppressor in a variety of human cancers, e.g., colorectal,
prostate, breast, liver and lung cancers [13,14,19,28].
Additionally, SOX7 may have potential usage as an inde-
pendent prognostic marker in prostate and lung cancers
as well as MDS patients [11,12,29]. Several lines of evi-
dence indicate SOX7 as a negative regulator of the Wnt/
β-catenin signaling pathway [14,15]. Of great interest, a
recent report based on whole genomic copy number
analysis demonstrates SOX7 as a novel tumor suppres-
sor, which is silenced in the majority of non-small cell
lung cancer (NSCLC) samples [19]. Molecules modulat-
ing SOX7 expression, such as miR-184 in hepatocellular
carcinoma (HCC), have also been reported [28]. Another
study published recently also showed that SOX7 could
suppress HCC in vivo and in vitro [30]. There are also
contradicting reports to demonstrate that SOX7 mRNA
was significantly up-regulated in several human cancer
cells [20]. These results have prompted us to hypothesize
that SOX7 might be a true tumor suppressor but behaves
differently in different cancers.
Conclusions
Our work reported here suggests, for the first time, that
SOX7 may play an important role as a tumor suppressor
in ovarian cancer progression. Our results also revealed
SOX7 as a negative regulator in the Wnt/β-catenin sig-
naling pathway in ovarian cancer. Although further stud-
ies are needed to elucidate the underlining mechanisms
of interactions between SOX7 and the Wnt/β-catenin
signaling pathway, our result demonstrates the suppres-
sive function of SOX7 in the carcinogenic process of
ovarian cancer.
Additional file
Additional file 1: Table S1. Short-listed 7933 genes were co-expressed
with SOX7 by Pearson correlation (FDR< 0.01) in GSE27651.
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